

FOR IMMEDIATE RELEASE

For more information, contact:

<p>Kevin M. Smith President & CEO CID4 kevin.smith@cid4.com (720) 859-4043</p>	
---	--

CID4 Announces Due Date for Spring 2013 New Project Consideration

The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is seeking its next Portfolio Company, and has set Tuesday April 2nd as the due date for submitting material to CID4.com for consideration.

Aurora, CO March 13, 2013 – The Colorado Institute for Drug, Device and Diagnostic Development (CID4), a 501(c)(3) not-for-profit entity focused on advancing the Colorado life science ecosystem through company creation and job growth, is seeking its next Portfolio Company. Tuesday April 2nd has been set as the deadline for submitting material for consideration.

CID4 maintains an online database for business plans to be submitted on a rolling basis. The database is more than just a location for project submissions for CID4 review; it is a powerful tool that enables industry partners and investors from all over world to reach into the technology-rich Colorado life science ecosystem. Providing an efficient, single point of entry, the database has been well received by both investors and Colorado entrepreneurs. Business plans uploaded to the CID4 database have been presented at numerous premiere partnering and investor conferences such as C21 BioVentures, BIO, and BioPartnering North America.

Those who submit their content by April 2nd will be considered by management and the CID4 Technical and Business Advisory Committee (TBAC). A use-of-proceeds budget for up to \$200,000 should be included with your submission. For details about the project selection process and where to submit materials, visit (<http://cid4.com/programs/applicaton>). Submissions received after the April 2nd deadline will be considered in the next project evaluation in approximately six months.

“We look forward to this next evaluation cycle and are excited to bring new innovations to our TBAC and Board of Directors,” said Kevin M. Smith, President and CEO of CID4. “Our first six Portfolio Companies have achieved important milestones in their drive to reach the market and improve healthcare. We are confident that our next investment will continue this record of commitment to progress.”

CID4 has committed \$1,650,000 to its first six Portfolio Companies, which have in turn raised over \$22 million in follow-on investment, grant or contract funding and created approximately 65 new, direct jobs. While working with its Portfolio investments, CID4 has continued to build

FOR IMMEDIATE RELEASE

our network with the sources of technology and funding within the State. CID4 is delivering on its mission of Economic Development through Innovation Advancement.

About the Colorado Institute for Drug, Device and Diagnostic Development

Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit <http://CID4.com>.

###